LB PHARMACEUTICALS INC(LBRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
LBRX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for LB PHARMACEUTICALS INC (LBRX), a Healthcare sector company. LBRX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), LB PHARMACEUTICALS INC reports net income of $-51.6M, free cash flow of $-38.0M. Top institutional holders of LBRX by reported 13-F value include Deep Track Capital, BlackRock, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. LBRX trades on the Nasdaq exchange and files with the SEC under CIK 1691082. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LB PHARMACEUTICALS INC directly from SEC EDGAR.
Net Income
Q2 2026
$-51.6M
Free Cash Flow
Q2 2026
$-38.0M
ROIC
Q2 2026
-62.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+60.1% YoYEPS (Diluted)
+98.2% YoYTotal Assets
+833.2% YoYOp. Cash Flow
+33.6% YoYFree Cash Flow
+34.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Net Income | $-25.2M +60.1% | $-63.1M | — |
| EPS (Diluted) | $-3.13 +98.2% | $-176.15 | — |
| Total Assets | $312.9M +833.2% | $33.5M | — |
| Operating Cash Flow | $-35.2M +33.6% | $-53.1M | — |
| Free Cash Flow | $-35.3M +34.5% | $-53.8M | — |
Get alerted when LBRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for LB PHARMACEUTICALS INC including:
Top Institutional Holders of LBRX
Deep Track Capital, LP
$108.8M3,352,804 shBlackRock, Inc.
$88.7M2,734,305 shRA CAPITAL MANAGEMENT, L.P.
$71.7M2,208,604 shTrails Edge Capital Partners, LP
$49.4M1,523,022 shJPMORGAN CHASE & CO
$48.9M1,497,293 shCommodore Capital LP
$48.7M1,500,000 shTCG Crossover Management, LLC
$47.0M1,447,310 shCaligan Partners LP
$46.7M1,438,070 shSpruce Street Capital LP
$44.7M1,376,159 shNantahala Capital Management, LLC
$34.2M1,052,894 sh
| Fund | Value | Shares |
|---|---|---|
| Deep Track Capital, LP | $108.8M | 3,352,804 |
| BlackRock, Inc. | $88.7M | 2,734,305 |
| RA CAPITAL MANAGEMENT, L.P. | $71.7M | 2,208,604 |
| Trails Edge Capital Partners, LP | $49.4M | 1,523,022 |
| JPMORGAN CHASE & CO | $48.9M | 1,497,293 |
| Commodore Capital LP | $48.7M | 1,500,000 |
| TCG Crossover Management, LLC | $47.0M | 1,447,310 |
| Caligan Partners LP | $46.7M | 1,438,070 |
| Spruce Street Capital LP | $44.7M | 1,376,159 |
| Nantahala Capital Management, LLC | $34.2M | 1,052,894 |
More Healthcare Companies
View all Healthcare →Put LBRX on your watchlist
Track score changes the day LB PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LBRX a good stock to buy?
13F Pro's AI-powered analysis of LB PHARMACEUTICALS INC (LBRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LBRX are available on the LBRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LBRX is classified as a small company.
Which hedge funds own LBRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LBRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LB PHARMACEUTICALS INC's investment landscape.